Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-cetuximab PET-guided cetuximab dose optimization in metastatic RAS wild-type colorectal cancer
NL-OMON26385Phase 2Recruiting
- Sponsor
- VU University Medical Center
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cetuximab in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) (3 cohorts), sponsored by VU University Medical Center. Primary endpoints: 89Zr-cetuximab uptake in non-hepatic metastases and correlation with clinical benefit, 89Zr-cetuximab uptake in non-hepatic metastases after cetuximab dose escalation and 1 more. Started May 2014; status: recruiting.
02
Drugs
cetuximab
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON26385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26385.